ESMO 2018 | Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC

Michel Ducreux, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, explores the emerging synergistic mechanisms of anti-androgenic agents and immune checkpoints inhibitors in hepatocellular carcinoma (HCC), in particular with reference to the combination of intravenous atezolizumab and bevacizumab, which has shown impressive responses in the first-line setting. Continuing on from this success, Prof. Ducreux highlights the attempts being made to further understand how this treatment compares with the current standard of care, sorafenib, in a Phase III trial and eagerly anticipates the results to emerge by the end of the year (IMbrave150; NCT03434379). This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.